Phase I
Meissa Vaccines’ intranasal live attenuated chimeric virus-based vaccine for SARS-CoV-2 (and its variants) recently was cleared for Phase I trials, which will start at the end of March.
With the rise of mutant strains of SARS-CoV-2 and the unlikelihood of 100% compliance in getting vaccines out, investigators are focusing on developing even better vaccines and new drugs that might be able to knock back the disease. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 23, 2021.
A COVID-19 nasal spray vaccine developed by Rokote Laboratories Finland Ltd., is preparing for Phase I trials in Finland…if it can win funding.
It was a relatively quiet week in terms of clinical trial news, but there were some significant releases. Here’s a look.
Findings from a second interim analysis of a first-in-human Phase I/II clinical trial of Translate Bio’s CF mRNA candidate, MRT5005, show the drug did not significantly improve lung function in patients with CF.
Amathus Therapeutics, a biopharmaceutical company working on small molecule modulators across diverse genetically defined diseases, has entered into a strategic collaboration with Merck to develop novel small molecule treatment candidates for neurodegenerative diseases.
Infectious disease-focused Vaccitech, which partnered with AstraZeneca and Oxford University on the development and manufacturing of that company’s COVID-19 vaccine, raised $168 million in a Series B financing round.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 16, 2021.
Nearly five years to the day after striking the deal, AVEO Oncology and CANbridge Life Sciences announce the termination of their collaboration and licensing agreement for AVEO’s AV-203.
PRESS RELEASES